|Bid||62.00 x 382500|
|Ask||0.00 x 252100|
|Day's Range||72.40 - 82.95|
|52 Week Range||68.00 - 162.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
By Anita Dushyanth, PhD NASDAQ:PULM Financial Update: On March 13, 2018 Pulmatrix (NASDAQ:PULM) reported financial results for fiscal 2017. Cystic Fibrosis Foundation Therapeutics (CFFT) is a nonprofit ...
The company, which bought rival SkyePharma for 441 million pounds in June 2016, said pretax loss stood at 102.2 million pounds against analysts' expectations of a loss of 88.7 million pounds, according to Thomson Reuters data. The asthma inhaler-maker said total royalties fell to 52.6 million pounds from 74.5 million pounds a year earlier. The company derives 35 percent of its revenue from royalties.
The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.
GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".
On November 9, 2017 Pulmatrix (PULM) announced their third quarter financial results and provided operational highlights. As a reminder, the global ABPA-asthma market is a multi-billion dollar opportunity with the U.S. representing close to two-thirds (~60%) of this industry. Management expects the Phase I studies supporting the PUR1900 program in both CF and severe asthma patients to create partnership opportunities for both indications.
LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Vectura Group plc (LSE:VEC), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and formulation business for inhaled airways products, today announces it is progressing the development ...
Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Vectura Group Plc a score of 28. Our analysis is based on comparing Vectura Group Plc with the following peers – ReNeuron Group plc, Hikma Pharmaceuticals Plc, Dechra Pharmaceuticals PLC, AstraZeneca PLC, GlaxoSmithKline plc, BTG plc, Sinclair Pharma plc and ECO Animal Health Group plc (RENE-GB, HIK-GB, ... Read more (Read more...)